In two Phase III trials, the compound known as evobrutinib failed to beat Sanofi’s established Aubagio in reducing MS relapse rates, Merck said in a statement late on Tuesday.
Tag Archive for: evobrutinib
The company’s CEO said its experimental multiple sclerosis drug can be a “blockbuster”, an industry term for annual sales that exceed $1 billion, even after concerns emerged that the drug may cause liver damage.
Novartis said no signs of liver damage had been seen in trials testing its anti-inflammatory drug candidate remibrutinib so far, voicing cautious optimism that it could elude the side effects that have beset rival products in the same drug class.
Merck KGaA said on Wednesday the U.S. Food and Drug Administration (FDA) had paused the initiation of new patients on its multiple sclerosis evobrutinib drug, knocking the German drugmaker’s share price.
